Stereotaxis targets $40M+ annual revenue with manufacturing ramp and product innovation in 2026 (NYSE:STXS)
Stereotaxis(US:STXS) Seeking Alpha·2026-03-10 00:18Management View - Stereotaxis, Inc. CEO David Fischel described 2025 as a year of "tremendous progress," highlighting technological and commercial advancements despite ongoing challenges [2] - The company aims to pioneer robotics within minimally invasive endovascular surgery, emphasizing its commitment to innovation in this field [2]